Cathie Wood’s ARK ETF published their daily trades for Monday, November 24th, 2025, showcasing a dynamic mix of strategic buys and sells.
Leading the day’s activity, ARK made a significant purchase of 437,345 shares of CoreWeave Inc (NASDAQ:CRWV), with a total investment of $31,335,769. This acquisition, primarily through the ARKK ETF, underscores ARK’s continued confidence in CoreWeave, a company known for its cloud computing services tailored for AI and machine learning workloads.
In contrast, ARK executed a substantial sell-off of GitLab Inc (NASDAQ:GTLB), unloading 646,911 shares valued at $26,840,337. This marks another day of divestment in GitLab, following a similar pattern observed in previous trading sessions, suggesting a strategic reevaluation of its position in the software development platform.
ARK also increased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by purchasing 42,404 shares worth $2,129,952. This move aligns with ARK’s ongoing interest in the biotech sector, particularly in gene-editing technologies.
Other notable transactions include the acquisition of 8,246 shares of Circle Internet Group Inc (NASDAQ:CRCL) for $588,187, and 13,402 shares of Bullish (BLSH) for $517,317. These investments reflect ARK’s diversified approach across different sectors.
On the selling side, ARK reduced its stake in Iridium Communications Inc (NASDAQ:IRDM) by 179,578 shares, amounting to $2,882,226. This continues a trend of reducing exposure to the satellite communications company over recent days.
Additionally, ARK sold 62,100 shares of Ibotta Inc (NASDAQ:IBTA) for $1,383,588 and made minor adjustments in Reddit Inc (NASDAQ:RDDT) with the sale of 100 shares worth $18,348.
Overall, ARK’s latest trading activity highlights its strategic focus on cloud computing and biotech, while trimming positions in select technology and communication stocks. Investors will be keen to see how these moves align with ARK’s broader investment strategies in the rapidly evolving market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.